Free tool
Medicare drug spending
Last checked: Nov 20, 2026Latest source record: 2024 calendar yearSource: CMS (Medicare Part D Spending by Drug : 2024-01-01; Medicare Part B Spending by Drug : 2024-01-01)Methods & limitations
Part D, 2024
$288.7B
Gross drug spending in the dataset
Part B, 2024
$60.8B
Gross drug spending in the dataset
Drugs listed
799
Part B
Total spending by year
- Part D
- Part B
View as table
| Year | Part D | Part B |
|---|---|---|
| 2020 | $194,092,038,339 | $37,778,829,680 |
| 2021 | $213,513,349,361 | $40,135,340,775 |
| 2022 | $239,779,215,689 | $44,241,259,745 |
| 2023 | $275,808,918,753 | $50,775,853,083 |
| 2024 | $288,667,842,058 | $60,838,164,403 |
Top 100 by total spending
2024 figures. Growth compares with 2023. Per-beneficiary ranks skip drugs with fewer than 11 beneficiaries.
| Drug | Part | Spending | Change | Beneficiaries | Per beneficiary | Per unit |
|---|---|---|---|---|---|---|
| Keytruda Pembrolizumab · J9271 | B | $5.99B | +10% | 75,361 | $79,464 | $55.72 |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj · J9144 | B | $2.53B | +22% | 26,517 | $95,426 | $49.11 |
| Prolia* Denosumab* · J0897 | B | $2.43B | +11% | 700,724 | $3,469 | $25.47 |
| Eylea Aflibercept · J0178 | B | $2.37B | -25% | 293,280 | $8,065 | $825.90 |
| Opdivo Nivolumab · J9299 | B | $1.93B | +1% | 26,951 | $71,752 | $30.71 |
| Vabysmo Faricimab-Svoa · J2777 | B | $1.92B | +48% | 172,503 | $11,120 | $34.47 |
| Membrane graft or membrane wrap, per square centimeter · Q4205 | B | $1.44B | +325% | 10,459 | $137,893 | $1,302.54 |
| Complete ft, per square centimeter · Q4271 | B | $1.17B | +18769% | 5,091 | $229,484 | $1,636.66 |
| Orencia* Abatacept* · J0129 | B | $930M | +3% | 33,154 | $28,062 | $42.48 |
| Imfinzi Durvalumab · J9173 | B | $843M | +14% | 14,791 | $56,999 | $79.68 |
| Entyvio Vedolizumab · J3380 | B | $769M | +6% | 19,661 | $39,134 | $21.79 |
| Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 · J1569 | B | $765M | +3% | 26,102 | $29,310 | $44.60 |
| Reblozyl Luspatercept-Aamt · J0896 | B | $755M | +67% | 6,466 | $116,808 | $39.53 |
| Restorigin, per square centimeter · Q4191 | B | $732M | +30150% | 5,256 | $139,204 | $1,481.65 |
| Comirnaty * Covid Vac (12up)(Raxt)/PF* · 91320 | B | $696M | +58% | 4,283,296 | $163 | $143.04 |
| Tecentriq Atezolizumab · J9022 | B | $678M | -10% | 10,191 | $66,497 | $83.43 |
| Ocrevus Ocrelizumab · J2350 | B | $669M | -4% | 11,764 | $56,845 | $57.58 |
| Eylea Hd Aflibercept · J0177 | B | $666M | n/a | 66,767 | $9,972 | $330.00 |
| Padcev Enfortumab Vedotin-Ejfv · J9177 | B | $641M | +106% | 5,839 | $109,818 | $35.32 |
| Evenity (2 Syringes) Romosozumab-Aqqg · J3111 | B | $639M | +42% | 52,146 | $12,261 | $10.73 |
| Helicoll, per square centimeter · Q4164 | B | $637M | +1143% | 2,421 | $263,250 | $1,521.68 |
| Ultomiris Ravulizumab-Cwvz · J1303 | B | $609M | +29% | 1,844 | $330,448 | $215.41 |
| Spikevax Covid Vac (12up)(Andu)/PF · 91322 | B | $597M | +17% | 3,479,068 | $172 | $152.66 |
| Enhertu Fam-Trastuzumab Deruxtecn-Nxki · J9358 | B | $581M | +25% | 8,410 | $69,140 | $26.95 |
| Fluzone High-Dose * Flu Vacc TS(65yr Up)/PF* · 90662 | B | $560M | +31% | 6,956,496 | $81 | $79.62 |
| Gammaked* Immune Globul G/Gly/Iga Avg 46* · J1561 | B | $545M | +18% | 15,316 | $35,580 | $48.29 |
| Prevnar 20 Pneumoc 20-Val Conj-Dip Crm/PF · 90677 | B | $525M | -9% | 1,840,975 | $285 | $282.44 |
| Yervoy Ipilimumab · J9228 | B | $509M | +11% | 8,483 | $59,960 | $170.60 |
| Botox* Onabotulinumtoxina* · J0585 | B | $479M | +8% | 165,103 | $2,899 | $6.22 |
| Actemra (J3262) Tocilizumab · J3262 | B | $463M | +11% | 19,715 | $23,495 | $5.89 |
| Sandostatin Lar Depot Octreotide Acetate,mi-Spheres · J2353 | B | $450M | +1% | 8,853 | $50,884 | $208.42 |
| Privigen Immun Glob G(Igg)/Pro/Iga 0-50 · J1459 | B | $440M | +17% | 13,330 | $33,026 | $47.21 |
| Rituxan Rituximab · J9312 | B | $437M | -10% | 22,261 | $19,630 | $76.27 |
| Vyvgart Efgartigimod Alfa-Fcab · J9332 | B | $417M | +40% | 1,803 | $231,053 | $31.47 |
| Xolair Omalizumab · J2357 | B | $415M | -1% | 17,605 | $23,566 | $37.24 |
| Ilumya Tildrakizumab-Asmn · J3245 | B | $413M | +20% | 9,049 | $45,684 | $134.38 |
| Syfovre Pegcetacoplan/PF · J2781 | B | $404M | +427% | 29,338 | $13,766 | $146.80 |
| Cimzia* Certolizumab Pegol* · J0717 | B | $398M | -1% | 25,557 | $15,559 | $4.55 |
| Kyprolis Carfilzomib · J9047 | B | $397M | -1% | 5,806 | $68,327 | $47.38 |
| Infliximab* Infliximab* · J1745 | B | $367M | -6% | 36,967 | $9,919 | $31.30 |
| NPlate Romiplostim · J2796 | B | $362M | +12% | 6,523 | $55,572 | $96.80 |
| Opdualag Nivolumab-Relatlimab-Rmbw · J9298 | B | $362M | +43% | 2,535 | $142,849 | $184.36 |
| Lanreotide Acetate (J1930)* Lanreotide Acetate* · J1930 | B | $354M | -4% | 7,615 | $46,454 | $48.23 |
| Libtayo Cemiplimab-Rwlc · J9119 | B | $348M | +29% | 5,482 | $63,500 | $27.11 |
| Soliris Eculizumab · J1300 | B | $337M | -19% | 956 | $352,952 | $219.00 |
| Simponi Aria Golimumab · J1602 | B | $330M | -10% | 33,452 | $9,865 | $11.44 |
| Dual layer impax membrane, per square centimeter · Q4262 | B | $318M | -77% | 1,678 | $189,626 | $1,093.57 |
| Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 · J1559 | B | $318M | +8% | 5,165 | $61,539 | $12.84 |
| Membrane wrap-hydro, per square centimeter · Q4290 | B | $310M | n/a | 1,807 | $171,399 | $1,898.83 |
| Fluad * Flu Vacc TS(65up)/Mf59c/PF* · 90653 | B | $303M | +113287% | 3,768,112 | $80 | $80.30 |
| Perjeta Pertuzumab · J9306 | B | $297M | -4% | 5,766 | $51,528 | $15.40 |
| Leqvio Inclisiran Sodium · J1306 | B | $296M | +107% | 48,298 | $6,135 | $11.95 |
| Krystexxa Pegloticase · J2507 | B | $283M | +15% | 1,097 | $257,821 | $3,319.64 |
| Amnicore pro+, per square centimeter · Q4299 | B | $281M | n/a | 1,474 | $190,882 | $2,367.31 |
| Neostim tl, per square centimeter · Q4265 | B | $274M | n/a | 1,202 | $228,090 | $2,073.58 |
| Trodelvy Sacituzumab Govitecan-Hziy · J9317 | B | $272M | +18% | 3,300 | $82,521 | $33.76 |
| Nucala Mepolizumab · J2182 | B | $267M | +5% | 8,671 | $30,829 | $29.70 |
| Abraxane* Paclitaxel Protein-Bound* · J9264 | B | $263M | -7% | 13,324 | $19,747 | $13.38 |
| Amnio quad-core, per square centimeter · Q4294 | B | $248M | n/a | 1,400 | $176,909 | $2,206.87 |
| Tepezza Teprotumumab-Trbw · J3241 | B | $246M | -10% | 962 | $256,201 | $321.05 |
| Fasenra* Benralizumab* · J0517 | B | $241M | +4% | 9,899 | $24,374 | $163.35 |
| Orion, per square centimeter · Q4276 | B | $235M | +184% | 984 | $238,833 | $1,330.78 |
| Complete aa, per square centimeter · Q4303 | B | $233M | n/a | 548 | $424,998 | $3,298.76 |
| Amnio-maxx or amnio-maxx lite, per square centimeter · Q4239 | B | $232M | +61497% | 1,858 | $124,681 | $2,387.81 |
| Hemlibra Emicizumab-Kxwh · J7170 | B | $230M | -1% | 438 | $525,221 | $52.49 |
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 · J1568 | B | $230M | +15% | 8,749 | $26,251 | $45.92 |
| Amvuttra Vutrisiran Sodium · J0225 | B | $229M | +37% | 603 | $379,824 | $4,787.75 |
| Tezspire Tezepelumab-Ekko · J2356 | B | $218M | +58% | 7,618 | $28,676 | $17.78 |
| Cimerli Ranibizumab-Eqrn · Q5128 | B | $217M | +77% | 38,028 | $5,703 | $228.24 |
| Eligard* Leuprolide Acetate* · J9217 | B | $213M | -1% | 141,546 | $1,506 | $177.55 |
| Elahere Mirvetuximab Soravtansine-Gynx · J9063 | B | $213M | +141% | 1,757 | $121,204 | $64.92 |
| Derm-maxx, per square centimeter · Q4238 | B | $204M | +5422% | 1,150 | $177,815 | $1,149.16 |
| Polivy Polatuzumab Vedotin-Piiq · J9309 | B | $202M | +69% | 3,042 | $66,241 | $124.68 |
| Tecvayli Teclistamab-Cqyv · J9380 | B | $200M | +127% | 1,549 | $129,048 | $30.74 |
| Izervay Avacincaptad Pegol Sodium/PF · J2782 | B | $190M | n/a | 18,308 | $10,398 | $108.34 |
| Adcetris Brentuximab Vedotin · J9042 | B | $187M | -3% | 1,363 | $137,180 | $230.36 |
| Amniowrap2, per square centimeter · Q4221 | B | $184M | +585% | 1,010 | $182,393 | $1,755.69 |
| Gazyva Obinutuzumab · J9301 | B | $184M | +13% | 5,252 | $34,943 | $70.96 |
| Tyvaso* Treprostinil* · J7686 | B | $183M | -11% | 1,226 | $149,284 | $730.43 |
| Yupelri Revefenacin · J7677 | B | $175M | +1% | 29,240 | $5,987 | $0.18 |
| Xwrap, per square centimeter · Q4204 | B | $164M | +409% | 928 | $176,846 | $2,807.89 |
| Avastin Bevacizumab · J9035 | B | $162M | -23% | 98,961 | $1,632 | $71.33 |
| Tysabri Natalizumab · J2323 | B | $159M | -14% | 2,778 | $57,169 | $23.41 |
| Cygnus dual, per square centimeter · Q4282 | B | $158M | +692% | 3,107 | $50,868 | $764.38 |
| Amnio tri-core amniotic, per square centimeter · Q4295 | B | $158M | n/a | 1,143 | $138,132 | $1,938.93 |
| Erbitux Cetuximab · J9055 | B | $158M | +1% | 3,387 | $46,542 | $72.98 |
| Aranesp (J0881) Darbepoetin Alfa In Polysorbat · J0881 | B | $152M | -3% | 39,338 | $3,859 | $2.93 |
| Vyvgart Hytrulo Efgartigimod-Hyaluronidas-Qvfc · J9334 | B | $151M | n/a | 902 | $167,216 | $32.40 |
| Darzalex Daratumumab · J9145 | B | $150M | -32% | 2,246 | $66,731 | $61.49 |
| Jemperli Dostarlimab-Gxly · J9272 | B | $142M | +295% | 1,770 | $80,337 | $230.86 |
| Kadcyla Ado-Trastuzumab Emtansine · J9354 | B | $142M | -2% | 2,206 | $64,448 | $38.53 |
| Mvasi Bevacizumab-Awwb · Q5107 | B | $141M | -13% | 13,212 | $10,697 | $25.83 |
| Cyramza Ramucirumab · J9308 | B | $138M | +3% | 3,080 | $44,726 | $68.94 |
| Vectibix Panitumumab · J9303 | B | $137M | +4% | 2,636 | $51,946 | $152.35 |
| Aralast NP* Alpha-1-Proteinase Inhibitor* · J0256 | B | $131M | +4% | 1,389 | $94,506 | $4.78 |
| Injectafer Ferric Carboxymaltose · J1439 | B | $131M | -11% | 73,218 | $1,793 | $1.10 |
| Lucentis Ranibizumab · J2778 | B | $129M | -67% | 33,741 | $3,821 | $159.40 |
| Truxima Rituximab-Abbs · Q5115 | B | $127M | -27% | 15,052 | $8,421 | $32.90 |
| Benlysta Belimumab · J0490 | B | $126M | +6% | 3,685 | $34,064 | $52.31 |
| Phesgo Pertuzumab-Trastuzumab-Hy-Zzxf · J9316 | B | $125M | +35% | 2,301 | $54,234 | $64.44 |
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.